In the BC EMT-6/CDDP model, the administration of anti-PD-L1 antibodies is effective as an adjuvant monotherapy, while the combination of anti-PD-L1 antibodies with paclitaxel and VEGF antagonists gives better efficiency results in a neoadjuvant setting [135]. Here, VEGFA is linked to breast cancer.